Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTRK-2 entrectinib basket study in NTRK/ROS1/ALK fusion-positive advanced solid tumors
2023-505034-10-00Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in Nonhematologic neoplasms and NTRK fusion-positive solid tumor, sponsored by Roche. Primary endpoint: Objective Response Rate. Started Aug 2016; status: completed.
02
Drugs
entrectinib
03
Conditions
Nonhematologic neoplasmsNTRK fusion-positive solid tumor
Beyond the preview
Go deeper on 2023-505034-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505034-10-00.